Advertisement

Topics

AACR 2018: Dual inhibition of IDO1 and PD-L1 safe in patients with advanced solid tumours

10:40 EDT 17 Apr 2018 | ecancermedicalscience

An immunotherapy treatment combining the IDO1 inhibitor epacadostat and the PD-L1 inhibitor durvalumab was found to be safe in patients with advanced solid tumours, with safety data similar to treatment with durvalumab alone, according to data presented...

Original Article: AACR 2018: Dual inhibition of IDO1 and PD-L1 safe in patients with advanced solid tumours

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: Dual inhibition of IDO1 and PD-L1 safe in patients with advanced solid tumours"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...